Therapy News and Research

RSS

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

The National Heart, Lung, and Blood Institute (NHLBI) has stopped a clinical trial evaluating a new approach to reduce the risk of recurrent stroke in children with sickle cell anemia and iron overload because of evidence that the new treatment was unlikely to prove better than the existing treatment.

5 Jun 2010

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, between 31 and 53 months after beginning oral appliance therapy, the sleep apnea treatment remained effective. Subjective daytime sleepiness, fatigue severity, and quality of life also remained improved.

5 Jun 2010

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

According to new research that will receive the Graduate Student Research Award on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the ratio between tongue volume and bony enclosure size in patients with obstructive sleep apnea may help dentists calculate oral appliance treatment success.

5 Jun 2010

US dental school graduates not adequately prepared to screen for sleep disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, the majority of U.S. dental schools have not adequately prepared their graduates to screen for sleep disorders, which affect more than 70 million adults in the U.S.

5 Jun 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

Researchers from University Hospitals Case Medical Center's Ireland Cancer Center will present new clinical research findings at the 46th Annual Meeting of The American Society of Clinical Oncology June 4-8 in Chicago.

5 Jun 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2010

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Patients with HER2-positive cancers can have dramatic responses to HER2-targeted drugs but eventually develop resistance to the agents. With that problem in mind, Fox Chase Cancer Center researchers are testing a novel type of antibody called MM-111 in patients with HER2-positive disease who have progressed on standard therapy.

5 Jun 2010

Nasendoscopies help predict response to OAT in sleep apnea patients

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, nasendoscopy may help dentists predict oral appliance therapy success in sleep apnea patients. Nasendoscopy involves a flexible endoscope being inserted through the nasal cavity. The tip of the scope is placed at the level of the velopharynx and oro-/hypopharynx.

5 Jun 2010

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva Pharmaceutical Industries Ltd. today announced positive results from a study assessing a new lower-volume injection of Copaxone® (glatiramer acetate) containing the currently approved dose in half the injection volume.

5 Jun 2010

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

A recent retrospective study by four Michigan physicians shows strong evidence that symptoms of headache, dizziness and anxiety in some patients with traumatic brain injury potentially could be alleviated or even eliminated with specialized eyeglass lenses containing prisms.

5 Jun 2010

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Center.

5 Jun 2010

Hip strengthening regimen proves effective at reducing PFP in female runners: Study

A twice weekly hip strengthening regimen performed for six weeks proved surprisingly effective at reducing -- and in some cases eliminating -- knee pain referred to as patellofemoral pain in female runners.

5 Jun 2010

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today important research findings that will be presented at the American Society of Clinical Oncology annual meeting taking place June 4 - 8, 2010 in Chicago. Research highlights include a comparison of first-line treatments for an aggressive form of lymphoma, the efficacy and safety of a new genetically engineered cancer therapy, and the value of a commonly used tool for staging lymphoma.

5 Jun 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Patients with high-grade gliomas who experience acute (early) neurological toxicity during their treatment were more likely to experience chronic (late) neurological toxicity and shortened overall survival, according to researchers from the Kimmel Cancer Center at Jefferson. The study will be presented at the 2010 ASCO Annual Meeting in Chicago (Abstract #2037).

5 Jun 2010

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2010

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.

5 Jun 2010

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

The University of Maryland, Baltimore's Office of Research and Development announced that Encore Path, Inc. of Baltimore signed an exclusive worldwide license agreement for a device technology invented jointly by researchers at the University of Maryland, Baltimore and the University of Maryland Baltimore County that helps stroke patients retrain their bodies to walk.

5 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

VA partners with National Institutes of Health to research on Parkinson's disease

Veterans and others with Parkinson's disease who undergo deep brain stimulation may benefit from research co-sponsored by the Department of Veterans Affairs and published recently in the prestigious New England Journal of Medicine.

5 Jun 2010

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Competitive Technologies, Inc. announced today that the Walter Reed Army Medical Center in Washington, D.C., has joined the growing list of organizations that will treat pain patients with CTT's Calmare Pain Therapy Treatment, as authorized by the Surgeon General of the U.S. Army and Commanding General of the U.S. Army Medical Command.

5 Jun 2010

Therapy News and Research

NHLBI stops trial evaluating new approach to reduce risk of recurrent stroke in children with sickle cell anemia

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

US dental school graduates not adequately prepared to screen for sleep disorders

New clinical research findings on oncology to be highlighted at ASCO 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Fox Chase Cancer Center announces first-in-human bi-specific HER2/HER3 pathway targeting antibody

Nasendoscopies help predict response to OAT in sleep apnea patients

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Prismatic eyeglass lenses reduce symptoms associated with TBI, vertical heterophoria: Study

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Hip strengthening regimen proves effective at reducing PFP in female runners: Study

John Theurer Cancer Center to showcase treatment advancements for cancer at ASCO 2010

Acute neurological toxicity associated with chronic neurological toxicity in patients with high-grade gliomas

Onyx presents interim results of Phase 1b dose-escalation carfilzomib combination trial for multiple myeloma

Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 2010

Encore Path signs license agreement for UMB technology that helps stroke patients redevelop natural gait

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

VA partners with National Institutes of Health to research on Parkinson's disease

Walter Reed Army Medical Center to treat pain patients with CTT's Calmare Pain Therapy Treatment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News